Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 11/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | GSK3A | P49840 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | PRKCB | P05771 | 1/20 | 0.39 |
| ▸ | PRKCA | P17252 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5682558 | 0.88 | GSK3B (0.48) | GSK3BPRKCBPRKCAKAT2B | |
| SCHEMBL12577577 | 0.73 | ALDH1A1 (0.57) | CNR1ALDH1A1 | |
| SCHEMBL5686110 | 0.72 | GSK3B (0.55) | GSK3BALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL12577609 | 0.69 | DRD4 (0.51) | CNR1ALDH1A1 | |
| SCHEMBL4424517 | 0.67 | CNR1 (0.52) | CNR1TP53ALDH1A1MEN1KMT2A | |
| SCHEMBL5682564 | 0.67 | PRKCB (0.53) | GSK3BGSK3APRKCBPRKCA | |
| SCHEMBL27950468 | 0.66 | PTGS2 (0.69) | GSK3BGSK3A | |
| SCHEMBL6700657 | 0.63 | GSK3B (0.44) | GSK3BGSK3AALDH1A1SMN1; SMN2 | |
| SCHEMBL22834000 | 0.62 | CNR1 (1.00) | CNR1TP53ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL4418818 | 0.62 | CHRM2 (0.51) | CNR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252045-A1 | Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby | WYETH | 2006-11-09 | — | — | US | disclosed |
| WO-2005028678-A9 | METHODS AND MATERIALS FOR IDENTIFYING AGENTS WHICH MODULATE BONE REMODELING AND AGENTS IDENTIFIED THEREBY | WYETH CORP (US) | 2006-08-31 | — | — | WO | disclosed |
| EP-1636388-A2 | METHODS AND MATERIALS FOR IDENTIFYING AGENTS WHICH MODULATE BONE REMODELING AND AGENTS IDENTIFIED THEREBY | Wyeth (US) | 2006-03-22 | — | — | EP | disclosed |
| WO-2005028678-A2 | METHODS AND MATERIALS FOR IDENTIFYING AGENTS WHICH MODULATE BONE REMODELING AND AGENTS IDENTIFIED THEREBY | WYETH (US) | 2005-03-31 | — | — | WO | disclosed |
| US-6719520-B2 | FOR INHIBITION OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3); TREATMENT AND PROPHYLAXIS FOR DIABETES, CHRONIC NEURODEGENERATIVE CONDITIONS, MOOD DISORDERS SUCH AS SCHIZOPHRENIA AND MANIC DEPRESSION AND HAIR LOSS AND CANCER | SMITHKLINE BEECHAM CORPORATION | 2004-04-13 | — | — | US | disclosed |
| US-20040010031-A1 | Novel method and compounds | SMITHKLINE BEECHAM P.L.C. | 2004-01-15 | — | — | US | disclosed |
| EP-1119548-A1 | PYRROLE-2,5-DIONES AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2001-08-01 | — | — | EP | disclosed |
| WO-2000021927-A2 | PYRROLE-2,5-DIONES AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2000-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040010031-A1 | Novel method and compounds | GSK3A, GSK3B, GSKIP | GSK3B 2/4885CNR1 1192/4885GSK3A 1/4885 |
| US-20060252045-A1 | Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby | BMP4, BMP2, BMP6 | GSK3B 2078/4885CNR1 1927/4885GSK3A 2144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.